QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:ORGO

Organogenesis - ORGO Stock Forecast, Price & News

$2.04
+0.01 (+0.49%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.02
$2.10
50-Day Range
$1.89
$2.93
52-Week Range
$1.86
$8.27
Volume
678,884 shs
Average Volume
1.32 million shs
Market Capitalization
$267.61 million
P/E Ratio
15.69
Dividend Yield
N/A
Price Target
$11.00

Organogenesis MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
439.2% Upside
$11.00 Price Target
Short Interest
Bearish
12.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.74mentions of Organogenesis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

379th out of 1,009 stocks

Pharmaceutical Preparations Industry

171st out of 494 stocks


ORGO stock logo

About Organogenesis (NASDAQ:ORGO) Stock

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGO Stock News Headlines

Adam Mesh: “This Strategy Saved My Trading Career”
Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. pixel
Adam Mesh: “This Strategy Saved My Trading Career”
Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. pixel
Organogenesis Holdings Inc. (ORGO)
See More Headlines
Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGO Company Calendar

Last Earnings
11/09/2021
Today
3/30/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORGO
Fax
N/A
Employees
1,030
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+439.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$15.53 million
Pretax Margin
4.50%

Debt

Sales & Book Value

Annual Sales
$450.89 million
Cash Flow
$0.27 per share
Book Value
$2.03 per share

Miscellaneous

Free Float
86,051,000
Market Cap
$267.61 million
Optionable
Not Optionable
Beta
1.55

Key Executives

  • Gary S. GillheeneyGary S. Gillheeney
    President, Chief Executive Officer & Director
  • Patrick R. Bilbo
    Chief Operating Officer
  • David Charles Francisco
    Chief Financial Officer
  • Lori H. Freedman
    Vice President & General Counsel
  • Robert Cavorsi
    Vice President - Strategy













ORGO Stock - Frequently Asked Questions

Should I buy or sell Organogenesis stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORGO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORGO, but not buy additional shares or sell existing shares.
View ORGO analyst ratings
or view top-rated stocks.

What is Organogenesis' stock price forecast for 2023?

2 brokerages have issued 12 month target prices for Organogenesis' stock. Their ORGO share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 439.2% from the stock's current price.
View analysts price targets for ORGO
or view top-rated stocks among Wall Street analysts.

How have ORGO shares performed in 2023?

Organogenesis' stock was trading at $2.69 on January 1st, 2023. Since then, ORGO shares have decreased by 24.2% and is now trading at $2.04.
View the best growth stocks for 2023 here
.

When is Organogenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ORGO earnings forecast
.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) announced its earnings results on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The company had revenue of $113.75 million for the quarter, compared to analysts' expectations of $112.10 million. Organogenesis had a trailing twelve-month return on equity of 9.83% and a net margin of 3.66%. During the same period in the prior year, the firm earned $0.19 EPS.

What ETFs hold Organogenesis' stock?
What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $450.00 million-$462.00 million, compared to the consensus revenue estimate of $501.90 million.

What other stocks do shareholders of Organogenesis own?
What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Soleus Capital Management L.P. (5.62%), AQR Capital Management LLC (1.67%), Morgan Stanley (1.51%), Millennium Management LLC (1.32%), Geode Capital Management LLC (1.12%) and Assenagon Asset Management S.A. (1.10%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Avista Capital Managing Member, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Glenn H Nussdorf, Michael W Katz, Michael W Katz, Starr Wisdom and Wayne D Mackie.
View institutional ownership trends
.

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $2.04.

How much money does Organogenesis make?

Organogenesis (NASDAQ:ORGO) has a market capitalization of $267.61 million and generates $450.89 million in revenue each year. The company earns $15.53 million in net income (profit) each year or $0.13 on an earnings per share basis.

How many employees does Organogenesis have?

The company employs 1,030 workers across the globe.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The official website for the company is organogenesis.com. The company can be reached via phone at (781) 575-0775 or via email at organoir@westwicke.com.

This page (NASDAQ:ORGO) was last updated on 3/30/2023 by MarketBeat.com Staff